Brachytherapy
Volume 8, Issue 3 , Pages 297-303 , July 2009

Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy

  • Adam Raben

      Affiliations

    • Department of Radiation Oncology, Helen F. Graham Cancer Center, Wilmington, DE
    • ,
  • Kyle E. Rusthoven

      Affiliations

    • Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, University of Colorado Denver, 1665 North Ursula Street, Suite 1032, Aurora, CO 80045. Tel.: +1-720-848-0100; fax: +1-720-848-0222.
    • ,
  • Abrihup Sarkar

      Affiliations

    • Department of Radiation Oncology, Helen F. Graham Cancer Center, Wilmington, DE
    • ,
  • Andrew Glick

      Affiliations

    • Brandywine Urology Consultants, Wilmington, DE
    • ,
  • Bruce Benge

      Affiliations

    • Brandywine Urology Consultants, Wilmington, DE
    • ,
  • Dayee Jacobs

      Affiliations

    • Department of Radiation Oncology, Helen F. Graham Cancer Center, Wilmington, DE
    • ,
  • David Raben

      Affiliations

    • Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO

Received 13 October 2008 ,Revised 25 November 2008 ,Accepted 17 December 2008.

References 

  1. Mettlin CJ, Murphy GP, Mcdonald CJ, et al. The National Cancer Data base report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer. 1999;86:1877–1882
  2. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol. 2003;169:1643–1652
  3. Zelefsky MJ, Yamada Y, Cohen G, et al. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: Improved dose distributions with an intraoperative computer-optimized conformal planning technique. Int J Radiat Oncol Biol Phys. 2000;48:601–608
  4. Raben A, Chen H, Grebler A, et al. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose. Int J Radiat Oncol Biol Phys. 2004;60:1631–1638
  5. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–1129
  6. Jani AB, Su A, Correa D, et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis. 2007;10:82–86
  7. Su AW, Jani AB. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol. 2007;30:215–219
  8. Raben A, Sammons S, Sim S, et al. Initial comparison of inverse optimization, modified peripheral technique, and geometric optimization as real-time intraoperative computer planning options for permanent seed implantation of the prostate. Brachytherapy. 2007;6:238–245
  9. Potters L, Calugaru E, Jassal A, et al. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?. Int J Radiat Oncol Biol Phys. 2006;6:1014–1019
  10. Zelefsky MJ, Yamada Y, Cohen GN, et al. Intraoperative real-time planned conformal prostate brachytherapy: Post-implantation dosimetric outcome and clinical implications. Radiother Oncol. 2007;84:185–189
  11. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  12. Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy. Cancer. 1999;85:2630–2637
  13. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995;22:209–234
  14. RTOG toxicity criteria. [RTOG website]. Available at: http://www.rtog.orgAccessed May 3, 2008
  15. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  16. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 125-iodine brachytherapy for prostate cancer. J Urol. 2005;173:803–807
  17. Foster W, Beaulieu L, Harel F, et al. The impact of 3D image guided prostate brachytherapy on therapeutic ratio: The Quebec University Hospital experience. Cancer Radiother. 2007;11:452–460
  18. Han BH, Wallner KE. Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications. Int J Cancer. 2001;96:372–378
  19. Snyder KM, Stone RG, Hong SM, et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;50:335–341
  20. Eade TN, Horwitz EM, Ruth K, et al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys. 2008;71:338–345
  21. Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261–1266
  22. Stone NN, Stocke RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology. 2007;69:338–342
  23. Wallner K, Merrick G, True L, et al. 125I versus 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003;57:1297–1303
  24. Lee WR, deGuzman AF, Bare RL, et al. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys. 2000;46:83–88
  25. Keyes M, Schellenberg G, Moravan V, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys. 2006;64:825–834
  26. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327–333

PII: S1538-4721(08)00703-4

doi: 10.1016/j.brachy.2008.12.004

Brachytherapy
Volume 8, Issue 3 , Pages 297-303 , July 2009

Article Tools

* Image Usage & Resolution